ADAMTS9 and nonpapillary renal cell carcinoma: Consistently, ADAMTS9-AS2 overexpression (Supplementary Figure 4A, P<0.05) and miR-27a-3p knockdown (Supplementary Figure 4B, P<0.05) led to the increased sensitivity of ccRCC cells to Cisplatin treatment, and both ADAMTS9-AS2 knockdown (Supplementary Figure 4C, P<0.05) and miR-27a-3p overexpression (Supplementary Figure 4D, P<0.05) contributed to the decreased sensitivity of ccRCC cells to Cisplatin.